IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group.
Lagging M, et al. Among authors: haagmans bl.
Hepatology. 2006 Dec;44(6):1617-25. doi: 10.1002/hep.21407.
Hepatology. 2006.
PMID: 17133471
Clinical Trial.